Ceribell, Inc., the developer of the first AI-powered point-of-care EEG diagnostic system, is revolutionizing seizure management in acute care. Ceribell’s mission is to make EEG diagnostics widely available, more efficient, and more cost-effective, to improve the detection and treatment of neurological conditions. The Ceribell system provides rapid access to accurate diagnostic information and continuous monitoring at the bedside 24/7, enabling precise patient care and hospital-wide efficiencies. The Ceribell system first received FDA 510(k) clearance in 2017 and is commercially available in the United States. The latest ClarityPro™ AI algorithm is the first and only FDA-indicated software for the diagnosis of Electrographic Status Epilepticus with U.S. Centers for Medicare and Medicaid Services approved New Technology Add-on Payment (NTAP).